Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis

NCT01690299 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01690299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01690299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
October 1, 2012
Completion date
April 4, 2016
Enrollment
250 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis, psoriatic arthritis